ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aripiprazole

Also written as “aripiprazole”, “Aripiprazole IM Depot” and “Antidepressant + Aripiprazole”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Tourette Syndrome · Autistic Disorder, led by 10 companies.

Drug pageAripiprazole: every studyMany companies study it; this page follows only the 124 they lead. All 292 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 26, 2004124 company-led studies, 1 open or runningNext primary completion: Sep 5, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only1120 open or runningphase 4since Mar 26, 2004May 7, 2002none ahead
Johnson & Johnson40 open or runningphase 4since Feb 10, 2012Feb 10, 2012none ahead
Abdi İbrahim Otsukaits history only10 open or runningphase 4since Feb 23, 2016Feb 23, 2016none ahead
Chengdu Kanghong Pharmaceutical Groupits history only10 open or runningno phasesince Jul 24, 2017Jul 24, 2017none ahead
CMG Pharmaceuticalits history only10 open or runningphase 1since Jun 4, 2015Jun 4, 2015none ahead
CSPC Pharmaceutical Groupits history only11 open or runningno phasesince Mar 23, 2026Mar 23, 2026Sep 5, 2027NCT07547384
Genovate Biotechnologyits history only10 open or runningphase 4since Oct 8, 2007Oct 8, 2007none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Mar 27, 2023Mar 27, 2023none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Aug 18, 2011Aug 18, 2011none ahead
H. Lundbeckits history only10 open or runningphase 3since Oct 7, 2013Oct 7, 2013none ahead

Also a collaborator on its studies: PRA Health Sciences, Covance and Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2012First study: phase 4 study in SchizophreniaFirst studyNCT01592201 · 13 enrolled · Korea, Republic of
  2. May 25, 2012Phase 1 study in HealthyNCT01607762 · 31 enrolled · Belgium
  3. Jun 2, 2015Phase 2 study in SchizophreniaNCT02462473 · 9 enrolled · United States
  4. Nov 2, 2015Phase 1 study in ImmunoassayNCT02634463 · 81 enrolled · Belgium

TargetBeta

“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
brexpiprazoleruleOtsukaphase 470

Studies

All 4 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02634463Immunoassay · Belgium1CompletedNov 9, 201681
NCT02462473Schizophrenia · United States2TerminatedJan 20169
NCT01607762Healthy · Belgium1CompletedApr 201231
NCT01592201Schizophrenia · Korea, Republic of4TerminatedJun 201313

How it is read

Names in the registry

  • “Aripiprazole”, 81 entries
  • “aripiprazole”, 13 entries
  • “Aripiprazole IM Depot”, 7 entries
  • “Antidepressant + Aripiprazole”, 2 entries
  • “Aripiprazole for Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.